Navigation Links
St. Francis Hospital to be Part of Major Nationwide Study Using a Catheter-Based Aortic Valve Replacement
Date:1/11/2011

ROSLYN, N.Y., Jan. 11, 2011 /PRNewswire/ -- Newell Robinson, M.D., Chairman of the Department of Cardiothoracic & Vascular Surgery; George Petrossian, M.D., Director of Interventional Cardiovascular Procedures; Andrew Berke, M.D., interventional cardiologist; and Roberto Colangelo, M.D., cardiothoracic surgeon at St. Francis Hospital, The Heart Center® are part of the medical team that is testing a device that may offer new hope for patients with symptomatic, severe aortic stenosis.

St. Francis Hospital has been selected as one of 40 centers nationwide to assess the Medtronic CoreValve system for transcatheter aortic valve implantation (TAVI), which has recently received conditional approval from the FDA for clinical trials.  St. Francis is one of the first hospitals in the U.S. to be activated as a site, and cardiologists have begun the process of implanting it in patients who are at high risk, or are ineligible, for open heart surgery.

Approximately 300,000 people worldwide (100,000 in the U.S.) have been diagnosed with the condition, which prevents the valve from opening completely, thereby preventing healthy blood flow from the aorta to the rest of the body.  But about one third of these patients are deemed at too high a risk for open heart surgery,(i) the only therapy with significant clinical effect that is currently available in the United States.  Although the CoreValve system has been implanted in 12,000 patients worldwide, it has not been available to patients in the U.S. until now.

The new valve replacement procedure channels a tube called a catheter with a prosthetic valve through the femoral artery to reach the heart.  The CoreValve System is designed with self-expandable technology, deploying the new valve inside the diseased aortic valve without open-heart surgery or surgical removal of the native valve.

"This is the most revolutionary device I've seen in my more than 20 years of being a cardiologist.  Nothing that I have witnessed in the past can change the way we practice interventional cardiology in such a dramatic way," says Dr. Petrossian.

"CoreValve has been used extensively in Europe.  The expectation is that we will be able to treat patients that otherwise we could not have treated, and be able to improve their lifestyles so they can stay out of heart failure for a longer period of time even though they aren't a candidate for surgery," says Dr. Robinson.

The Hospital's Chairman of Cardiology, Richard Shlofmitz, M.D., was instrumental in bringing the study to St. Francis.  He sees a time in the future when the benefits of these innovative devices will be available to a broader segment of patients who are not a high risk for surgery.  "This new approach is likely to have the same impact on the treatment of valvular disease as stenting did on coronary artery disease."

For more information about the study, log on to www.clinicaltrials.gov.  For more information about enrolling in the study, call (516) 562-6790, or visit www.stfrancisheartcenter.com.

Contact: Paul Barry, 516-705-6657, paul.barry@chsli.org

Rosemary Gomez, 516-705-6656, rosemary.gomez@chsli.org

(i) Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2003;26:2714-2720.


'/>"/>
SOURCE St. Francis Hospital
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
3. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
4. St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures
5. Marc J. Fagel of the U.S. Securities and Exchange Commission to Discuss SEC Enforcement at CBIs Biotech/Pharma Finance and Accounting Forum in San Francisco
6. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
9. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
10. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
11. BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  A new study by ... the use of opioid therapy to treat chronic pain ... likelihood of more harmful consequences, including death. ... and Zankhana Mehta , M.D., authored the study ... chronic opioid therapy. The study was published in the ...
(Date:12/8/2016)... 2016 Mederi Therapeutics Inc . hat die behördliche Zulassung ... für gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance ... in and around the Cape Coral area, is embarking on a charity drive with ... Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide ...
Breaking Medicine News(10 mins):